Use of selective serotonin reuptake inhibitors (SSRIs) in women delivering liveborn infants and other women of child-bearing age within the U.S. Food and Drug Administration’s Mini-Sentinel program

Archives of Women's Mental Health

Volumn 19, Issue 6, 2016, Pages 969-977

  Andrade, Susan E ^a   Reichman, Marsha E ^b   Mott, Katrina ^b   Pitts, Marilyn ^b   Kieswetter, Caren ^b   Dinatale, Miriam ^b   Stone, Marc B ^b   Popovic, Jennifer ^c   Haffenreffer, Katherine ^c   Toh, Sengwee ^c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Pregnancy; Prevalence; Selective serotonin reuptake inhibitors

Indexed keywords

CITALOPRAM; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADOLESCENT; ADULT; ANXIETY DISORDER; ARTICLE; CHILD; CONTROLLED STUDY; DATA BASE; DEPRESSION; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE SYSTEM; HUMAN; LIVE BIRTH; OUTPATIENT; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED STATES; PREGNANCY COMPLICATION; PREVALENCE; PSYCHOLOGY; SENTINEL SURVEILLANCE; STATISTICS AND NUMERICAL DATA;

ADULT; DEPRESSIVE DISORDER; FEMALE; HUMANS; LIVE BIRTH; PREGNANCY; PREGNANCY COMPLICATIONS; PREVALENCE; SENTINEL SURVEILLANCE; SEROTONIN UPTAKE INHIBITORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84968615943     PISSN: 14341816     EISSN: 14351102     Source Type: Journal    
DOI: 10.1007/s00737-016-0637-1     Document Type: Article

References (27)

1. Andrade SE, Davis RL, Cheetham TC et al (2012) Medication exposure in pregnancy risk evaluation program. Matern Child Health J 16:1349–1354
2. Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, Rolnick SJ, Roblin D, Smith DH, Willy ME, Staffa JA, Platt R (2008) Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 198:194.e1–194.e5
3. Andrade SE, Toh S, Houstoun M et al (2016) Surveillance of medication use during pregnancy in the Mini-Sentinel program. Matern Child Health J 20(4):895–903
4. Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R (2011) Developing the Sentinel System—a national resource for evidence development. N Engl J Med 364:498–499
5. Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR (2004) Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 103:698–709
6. Bobo WV, Epstein RA Jr, Hayes RM, Shelton RC, Hartert TV, Mitchel E, Horner J, Wu P (2014) The effect of regulatory advisories on maternal antidepressant prescribing, 1995–2007: an interrupted time series study of 228,876 pregnancies. Arch Womens Ment Health 17:17–26
7. Bonari L, Pinto N, Ahn E, Einarson A, Steiner M, Koren G (2004) Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 49:726–735
8. Cooper WO, Willy ME, Pont SJ, Ray WA (2007) Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 196:544.e1–544.e5
9. Curtis LH, Weiner MG, Boudreau DM et al (2012) Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf 21(Suppl 1):23–31
10. Gavin NI, Gaynes BN, Lohr KN, Melzer-Brody S, Gartlehner G, Swinson T (2005) Perinatal depression. Obstet Gynecol 106:1071–1083
11. Gentile S (2011) Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of birth defects. Acta Psychiatr Scand 123:266–275
12. Huybrechts KF, Palmsten K, Mogun H et al (2013) National trends in antidepressant medication treatment among publicly-insured pregnant women. Gen Hosp Psychiatry 35(3):265–271
13. Kawai AT, Li L, Kulldorff M, et al. (2014) Mini-Sentinel CBER/PRISM surveillance protocol influenza vaccines and pregnancy outcome. Version 2. http://www.mini-sentinel.org/work_products/PRISM/Mini-Sentinel_PRISM_Influenza-Vaccines-and-Pregnancy-Outcomes-Protocol.pdf. Accessed 8 Sept 2015
14. Le Strat Y, Dubertret C, Le Foll B (2011) Prevalence and correlates of major depressive episode in pregnant and postpartum women in the United States. J Affect Disord 135:128–138
15. Li Q, Andrade SE, Cooper WO et al (2013) Validation of an algorithm to estimate gestational age in electronic health plan databases. Pharmacoepidemiol Drug Saf 22:524–532
16. Melville JL, Gavin A, Guo Y, Fan MY, Katon WJ (2010) Depressive disorders during pregnancy: prevalence and risk factors in a large urban sample. Obstet Gynecol 116:1064–1070
17. Meunier MR, Bennett IM, Coco AS (2013) Use of antidepressant medication in the United States during pregnancy, 2002–2010. Psychiatr Serv 64:1157–1160
18. Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S, National Birth Defects Prevention Study (2011) Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. Am J Obstet Gynecol 205:51.e1–51.e8
19. Myles N, Newall H, Ward H, Large M (2013) Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Aust N Z J Psychiatry 47:1002–1012
20. Platt R, Carnahan RM, Brown JS et al (2012) The U.S. Food and Drug Administration’s Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf 21(Suppl 1):1–8
21. Reefhuis J, Devine O, Friedman JM, Louik C, Honein MA, National Birth Defects Prevention Study (2015) Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports. BMJ 351:h3190
22. Rosati K, Evans B, McGraw D (2011) HIPAA and common rule compliance in the Mini-Sentinel pilot, white paper. http://www.mini-sentinel.org/work_products/About_Us/HIPAA_and_CommonRuleCompliance_in_the_Mini-SentinelPilot.pdf [serial online]. Accessed 8 Sept 2015
23. U.S. Food and Drug Administration (2004) FDA Medwatch drug alert on Effexor and SSRIs. June 3, 2004. Effexor and Effexor XR (venlafaxine HCl) http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm154975.htm. Accessed 8 Sept 2015
24. U.S. Food and Drug Administration (2005) FDA public health advisory: paroxetine. December 8, 2005. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm051731.htm. Accessed 8 Sept 2015
25. U.S. Food and Drug Administration (2006) FDA alert [7/2006]: increased risk of neonatal persistent pulmonary hypertension. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm085313.htm. Accessed 8 Sept 2015
26. U.S. Food and Drug Administration (2011) FDA drug safety communication: selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies. December 14, 2011. http://www.fda.gov/Drugs/DrugSafety/ucm283375.htm. Accessed 8 Sept 2015
27. Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, Ramin S, Chaudron L, Lockwood C (2009) The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol 114:703–713